List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.

  1. Development of Anti-Microbial Peptide Therapeutics

    SBC: TENSIVE CONTROLS, INC.            Topic: 83

    A safe food supply is critical to the well being of any society. However, in highly urbanized societies, the number of people affected by a contaminated food source can be huge. Antibiotic resistant disease in the U.S. is an escalating problem [2, 3]. Much of this problem is a result of the use of antibiotics in production animals, where they prevent disease. Chronic use results in the emergence o ...

    SBIR Phase I 2014 Department of Agriculture
  2. Development of TAK1 Compounds for Neonatal Onset Multisystem Inflammatory Disease

    SBC: CONFLUENCE LIFE SCIENCES, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Cryopyrin-associated periodic syndromes (CAPS) are a family of rare autoinflammatory diseases of which neonatal-onset multisystem inflammatory disease (NOMID) is the most severe phenotype. NOMID is characterized by NLRP3 activating mutations resulting in excessive interleukin- 1?IL-1?and IL-18 production associated with recurrent fever, rash, skeletal lesions, ...

    SBIR Phase I 2014 Department of Health and Human Services
  3. AAAPT Technology for Improving Chemotherapy

    SBC: Sci-Engi-Medco Solutions, Inc            Topic: NCI

    DESCRIPTION provided by applicant Dysregulation of apoptosis pathways and loss of Human Beta Defensin hBD are the common tactics adapted by cancer cells to circumvent the effects of chemotherapy Consequently high dose of chemotherapy is required to obtain a clinically relevant therapeutic index which in turn compromises safety and develops resistance to therapy The problem is acute p ...

    SBIR Phase I 2014 Department of Health and Human Services
  4. Developing a standardized kit and normal reference profile for circular RNAs in the nervous system

    SBC: COFACTOR GENOMICS, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): Modified ribonucleic acids (RNA) are important regulators of translation and other cellular pathways. Non- coding RNAs like microRNAs play significant roles in neuronal development, and can serve as biomarkers for psychiatric disorders. Another such modified RNA is circular RNA (circRNA), a non-coding transcript present in the cytoplasm. Since circRNAs are pres ...

    SBIR Phase I 2014 Department of Health and Human Services
  5. A new two-drug combination therapy for noise-induced hearing loss

    SBC: GATEWAY BIOTECHNOLOGY, INC.            Topic: NIDCD

    DESCRIPTION (provided by applicant): Noise is the most common occupational and environmental hazard, thus it is not surprising that noise-induced hearing loss (NIHL) is the second most common form of sensorineural hearing deficit, second only to age-related hearing loss (presbycusis). Although therapeutics that target the free radical pathway have shown promise for reducing NIHL, there are no FDA- ...

    SBIR Phase I 2014 Department of Health and Human Services
  6. Calcaftor, a CFTR stabilizer for Cystic Fibrosis treatment

    SBC: Calista Therapeutics, Inc.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Calista Therapeutics has invented Calcaftor, a first-in-class peptide drug that can treat all Cystic Fibrosis (CF) patients. Calcaftor is validated in the gold standard pre-clinical model of CF using F508 -CFTR lung tissue harvested from CF transplant patients. Results from this model demonstrated a gt25 hour duration of action that enables once daily inhaled n ...

    SBIR Phase I 2014 Department of Health and Human Services
  7. Novel Inhaled Therapy for Idiopathic Pulmonary Fibrosis

    SBC: ANTEGRIN THERAPEUTICS, INC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Idiopathic pulmonary fibrosis (IPF) is a deadly lung disease that affects an estimated 133,000 patients in the U.S. and more than 5 million worldwide. Median survival time after diagnosis is only 2-3 years, with a 5-year mortality rate exceeding 50%. IPF is the leading indication for lung transplant in most large treatment centers. The hallmark of the disease i ...

    SBIR Phase I 2014 Department of Health and Human Services
  8. Manufacturing of Growth Factors to Enable Cardiopoietic Stem Cell Therapy for Hea

    SBC: APT THERAPEUTICS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Cardiopoietic cell therapy significantly improved left ventricular function, blunted pathological remodeling, and functional outcomes in animal models and Phase I/II clinical trial of heart failure patients. There is ongoing Phase III trial. In this therapeutic approach, bone marrow-derived mesenchymal stem cells are engaged into cardiac stem cells by exposing ...

    SBIR Phase I 2014 Department of Health and Human Services
  9. Inter-alpha-inhibitors in Hypoxic-Ischemic Brain Injury

    SBC: PROTHERA BIOLOGICS, LLC            Topic: NINDS

    DESCRIPTION (provided by applicant): Neonatal hypoxia-ischemia (HI) remains a major cause of acute perinatal brain injury, leading ultimately to neurologic dysfunction manifesting as cerebral palsy, mental retardation, and epilepsy. Cerebral oxygen deprivation and/or reduced blood flow due to umbilical cord occlusion, prolonged labor, and/or intracranial hemorrhage produce an inflammatory respons ...

    SBIR Phase I 2014 Department of Health and Human Services
  10. Low-dose IL2-based Immunomodulatory therapy for Stroke

    SBC: APT THERAPEUTICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): It has been recently shown that CD4+ and CD8+ T lymphocytes are critically involved in the collateral brain injury and neurological deficit associated with experimental stroke. Naturally occurring CD4+CD25+Foxp3+ (nTreg) cells derived from thymus play a key role in modulating the function of effector T cells and antigen- presenting cells that maintain self tole ...

    SBIR Phase I 2014 Department of Health and Human Services

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government